DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium

Information source: Chiang Mai University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Delirium

Intervention: quetiapine (Drug); haloperidol (Drug)

Phase: Phase 3

Status: Terminated

Sponsored by: Chiang Mai University

Official(s) and/or principal investigator(s):
Benchalak Maneeton, Assoc Prof, Principal Investigator, Affiliation: Department of Psychiatry,Faculty of Medicine, Chiang Mai university, Thailand

Summary

The purpose of this study is to determine whether quetiapine, and haloperidol are effective and safe in the treatment psychiatric symptoms in patients with delirium.

Clinical Details

Official title: Compare Efficacy and Safety Between Quetiapine and Haloperidol in Treatment Delirium

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: decrease in delirium rating scale and clinical global improvement

Secondary outcome: compare extrapyramidal and other report side effects of quetiapine and haloperidol from modified Simpson Angus scale and other report side effects.

Detailed description: A delirious state often founds in general hospitals and remains a significant cause of death. Existing methods of treatment includes identification and elimination of factors contributing to the delirium in addition to pharmacological and nonpharmacological treatment interventions (Trzepacz et al., 1999). Antipsychotics can play an important role in the management of the symptoms of delirium.

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female age 18 -75 years

- Was admitted in Maharaj Nakhon Chiang Mai hospital

- Was diagnosed by the diagnostic criteria for DSM-IV-TR delirium due to a general

medical condition or delirium due to multiple etiologies

- Delirious state (delirium) of the patients was confirmed by using name-assess

confusion assessment method (CAM) and assessment of severity with delirium rating scale-revised-98 (DRS-R-98)

- Have a written consent from the legal representatives

Exclusion Criteria:

- Was diagnosed substance withdrawal delirium

- Having a history drug allergy either from quetiapine or haloperidol

- Female patients who are pregnant or breastfeeding

- No written consent from the legal representatives

- Received other anti-psychotic drug before attend the study

- Being ill with renal or hepatic failure

Locations and Contacts

Department of psychiatry, faculty of medicine, Chiang Mai university, Chiang Mai 50200, Thailand
Additional Information

treatment delirium

treatment delirium

treatment delirium

treatment delirium

Starting date: June 2009
Last updated: June 22, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017